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Abstract
Driver mutations in the two histone 3.3 (H3.3) genes, H3F3A and H3F3B, were recently identified by whole
genome sequencing in 95% of chondroblastoma (CB) and by targeted gene sequencing in 92% of giant cell
tumour of bone (GCT). Given the high prevalence of these driver mutations, it may be possible to utilise these
alterations as diagnostic adjuncts in clinical practice. Here, we explored the spectrum of H3.3 mutations in a
wide range and large number of bone tumours (n 5 412) to determine if these alterations could be used to
distinguish GCT from other osteoclast-rich tumours such as aneurysmal bone cyst, nonossifying fibroma, giant
cell granuloma, and osteoclast-rich malignant bone tumours and others. In addition, we explored the driver
landscape of GCT through whole genome, exome and targeted sequencing (14 gene panel). We found that
H3.3 mutations, namely mutations of glycine 34 in H3F3A, occur in 96% of GCT. We did not find additional
driver mutations in GCT, including mutations in IDH1, IDH2, USP6, TP53. The genomes of GCT exhibited few
somatic mutations, akin to the picture seen in CB. Overall our observations suggest that the presence of
H3F3A p.Gly34 mutations does not entirely exclude malignancy in osteoclast-rich tumours. However, H3F3A
p.Gly34 mutations appear to be an almost essential feature of GCT that will aid pathological evaluation of
bone tumours, especially when confronted with small needle core biopsies. In the absence of H3F3A p.Gly34
mutations, a diagnosis of GCT should be made with caution.
Keywords: H3F3A; H3F3B; giant cell tumour of bone; malignant giant cell tumour of bone; giant cell granuloma; solid variant of
aneurysmal bone cyst; USP6
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Introduction
Giant cell tumours of bone (GCT) account for
approximately 5% of all primary bone tumours and
generally affect the epiphysis of long bones in skele-
tally mature individuals. They are classified as
locally aggressive and rarely metastasising neoplasms
[1]. When GCT metastasise, they spread to the lungs
but notably the morphology remains similar to the
primary lesion and the disease is generally controlled
by resection alone. Such an event is referred to as
‘benign metastasing’ disease. Although the majority
of GCTs presents with a characteristic combination
of clinical, radiological and histological findings,
some remain diagnostically challenging, particularly
on small needle core biopsies [1]. Due to varying his-
tological appearances within and between individual
GCT and due to morphologic overlap with other bone
tumours, the differential diagnoses include osteoclast-
rich osteosarcomas which often represent telangiectatic
osteosarcoma, and high grade sarcoma arising within a
conventional GCT (malignant GCT), along with sev-
eral benign mimics comprising aneurysmal bone cyst
(ABC), chondroblastoma (CB), nonossifying fibroma
(NOF) and giant cell granuloma (GCG) occurring
exclusively in the jaws and in the small tubular bones
of the hand and feet [2,3]. Less likely, GCT can also
be mistaken for osteoid osteoma/osteoblastoma and
tenosynovial giant cell tumour.
Recently, we reported the whole genomes of 6 CB
which harboured p.Lys36Met (p.K36M) mutations in
the paralogous histone 3.3 genes (H3.3), H3F3A (1/
6) and H3F3B (5/6). The finding was confirmed in
an extended targeted sequencing analysis detecting
these mutations in 73/77 CB. Due to similarities in
morphology and site of presentation, we also
screened a series of GCT for H3.3 mutations. We
found H3.3 mutations in 92% of cases (49/53), exclu-
sively in the H3F3A gene which all occurred at gly-
cine 34. H3F3A p.Gly34Trp (p.G34W) alterations
were found in all but one case of GCT which har-
boured a p.G34L mutation. We additionally identified
distinct H3.3 mutations in 2/103 osteosarcomas (one
p.G34R in H3F3A, and one p.G34R mutation in
H3F3B) and in 1/75 chondosarcomas (H3F3A
p.K36M) [2]. Since then, others have reported a
H3F3A mutation in another osteosarcoma (1/10,
p.G34W) [3].
In addition to H3F3A and H3F3B mutations, other
somatic mutations may potentially be of diagnostic
value in the clinic for classifying osteoclast-rich
lesions of bone. Such mutations include rearrange-
ments involving USP6 which forms a fusion gene
with a number of partners including CDH11, ZNF9,
COL1A1, TRAP150 and OMD. These are found in
approximately 75% of primary ABC [4–6] but have
not been found in a screen of 9 GCT [4,5]. In addi-
tion, fusions involving macrophage colony-
stimulating factor 1 have been described in tenosyno-
vial giant cell tumours. Unfortunately this is of lim-
ited diagnostic value as it is only detectable in a
minority of tumour cells [7]. Furthermore, IDH2
mutations, which also affect central chondrosarcoma
[8], have recently been reported to occur in 80% of
GCT (16/20) [9].
In this study, we sequenced the whole genomes of
five and whole exome of one GCT to search for driver
mutations other than H3.3 mutations. In addition, we
sought to define the specificity of p.G34W alterations
for GCT by screening 91 GCT as well as a series of
321 osteoclast-rich lesions including ABC, CB, NOF,
GCG, osteoblastoma/osteoid osteoma, TGCT, in addi-
tion to malignant osteoclast-rich tumours of bone.
Materials and methods
Patient samples
Formalin-fixed paraffin-embedded cases were
retrieved from the diagnostic pathology archives at
the Royal National Orthopaedic Hospital (RNOH)
and from the Basel Bone Tumour Reference Centre
(BBTRC). All samples were reviewed by specialist
bone tumour pathologists at RNOH (AMF, MFA, RT)
and BBTRC (DB) and diagnosed according to the cur-
rent WHO classifications [10,11] (Supporting Informa-
tion Tables 1 and 2). Individual cases were correlated
with clinical and radiological information where avail-
able. Tissue sample types are provided in Supporting
Information Table 3. In cases in which the histology
and mutational analysis did not match, the morphol-
ogy was re-evaluated independently by all members of
the RNOH pathology team and a consensus diagnosis
was subsequently reached by all pathologists.
Ethical approval was obtained from the Cam-
bridgeshire 2 Research Ethics Service (reference 09/
H0308/165), the UCL Biobank for Health and Dis-
ease ethics committee (covered by the Human Tissue
Authority licence 12055: project EC17.1) and from
the Ethikkommission beider Basel (reference 274/12).
Whole genome and exome sequencing
DNA from GCT and matching non-neoplastic tissue,
derived from 6 individuals, was subjected to whole
genome (n 5 5) or exome (n 5 1) sequencing as
described previously [12], using Illumina Hiseq 2000
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analysers (Illumina Inc, CA). Reads were aligned to
the reference human genome (NCBI37) by burrows
wheeler aligner (BWA) on default settings [13].
Unmapped reads and polymerase chain reaction-
derived duplicates were excluded. Relevant coverage
metrics are summarised in Table 1.




A pooled barcoded amplicon-tagged library generated
using Fluidigm
VR
Access ArrayTM (Fluidigm Europe
B.V, Amsterdam, Netherlands) was diluted for direct
input into the emulsion polymerase chain reaction
(PCR) with Ion SphereTM particles with Ion PGMTM
Template OT2 200 Kit (Ion OneTouchTM system)
following the manufacturer’s instructions (Life Tech-
nologies Ltd, Paisley, Scotland). The pooled samples
were sequenced using 316 chip with Ion PGMTM 200
Sequencing kit on the Ion Torrent PGMTM sequencer
following manufacturer instructions (Life Technolo-
gies). Targeted hotspot mutations as reported in
COSMIC in 14 genes, including EGFR, KRAS,
NRAS, BRAF, IDH1, IDH2, KIT, GNAS1, CTNNB1,
PTEN, PDGFRA, H3F3A, H3F3B, TP53 (covering in
total 50 amplicons) were analysed (Supporting
Table 1. Overview of giant cell tumours of bone genomes and exomes
PD21292a PD21294a PD21295a PD21296a PD7524a PD9999a
Genome/exome Genome Genome Genome Genome Genome Exome
Tumour coverage 51.26 41.42 56.22 48.48 39.04 60% covered by
at least 303
Normal coverage 25.93 22.56 23.28 26.1 34.26 60% covered by
at least 303











Structural changes 0 0 0 0 LOH 5q and 8p n.a.
Substitutions 479 977 739 700 815 7
Precision* 0.90 0.90 0.93 0.90 0.81 All reviewed
Coding 5 6 9 11 12 7
Non-synonymous 4 4 7 7 8 7
Truncating 0 1 0 1 2 0
Indels 54 79 102 46 45 0
Precision* 0.76 0.84 0.61 0.91 0.93 n.a.
Coding 0 0 0 0 0 0
In frame 0 0 0 0 0 0
Out of frame 0 0 0 0 0 0
Driver mutation H3F3A G34W H3F3A G34W** H3F3A G34W H3F3A G34W H3F3A G34W H3F3A G34W
*Based on review of 100 (or less, where fewer mutations were called) randomly selected variants.
**Manually called.
n.a.—not applicable.
Table 2. Results of the targeted genetic anlysis for H3F3A and H3F3B and USP6 rearrangment






















GCT 91 83 0 1 1 0 0 2 4 89
GCT of small bones 25 14 2 0 0 0 0 3 6 21
CB 7 0 0 0 0 5 2 0 0 7
ABC 44 2 0 0 0 0 1 32 9 41
NOF 66 4 0 0 0 0 0 0 62 62
Tenosynovial giant cell Tumour 51 0 0 0 0 0 0 0 51 51
Osteoblastoma 21 0 0 0 0 0 0 0 21 21
Osteoid osteoma 9 0 0 0 0 0 0 0 9 9
Giant cell granuloma of jaw (solitary) 78 0 0 0 0 0 0 0 78 78
Adamantinoma 8 0 0 0 0 0 0 0 8 8
Osteofibrous dysplasia 6 0 0 0 0 0 0 0 6 6
Total no of mutations 103 2 1 1 5 3 37 252
*Diagnosis revised following review of histology and imaging on discovery of the genetic alterations
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Information Table 4 for primer details and descrip-
tion of hot-spots targeted).
Reads were aligned to the reference genome hg19
and binary alignment map (BAM) files were gener-
ated using Ion torrent suite version 4.0.1. Reads were
visualised using integrative genomics viewer (IGV)
[14] with the appropriate browser extensible data
(BED) files for all 14 genes.
Results
Whole genome/exome sequencing of GCT
To perform a genome-wide search for driver muta-
tions in GCT, DNA from 5 tumours and blood from
the same patients, were studied by whole genome
sequencing, and one tumour was subjected to whole
exome sequencing. Overall, few somatic changes
were seen. In the five genomes, a median of 739 sub-
stitutions (range 479–977) and 54 indels (range 45–
102) were present (Supporting Information Table 5).
Including the additional tumour studied at whole
exome level, overall 50 coding substitutions, 37 of
which were nonsynonymous and no coding indels
were found. Other than H3F3A p.G34W mutations,
no driver event was discernible amongst nonsynony-
mous mutations. No rearrangements or copy number
changes were identified, bar two regions of loss of
heterozygosity in one of the five genomes (PD7524a)
(Supporting Information Figure 1).















S00033676 2012 ALIVE 33 M Talus, left Malignant
osteoclast-rich
tumour
WT H3F3A/B WT IDH1/2 WT
S00033682 2005 Lost in
follow up





WT H3F3A/B WT IDH2 R132S
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WT H3F3A/B WT IDH1/2 WT
S00039484 2004 DOD
(10/2007)







WT H3F3A/B WT IDH1/2 WT
S00039476 1998, 2005,
2009





WT H3F3A G34W/A IDH1/2 WT




WT H3F3A G34W/A IDH1/2 WT





WT H3F3A/B WT IDH1/2 WT
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Figure 1. A sacral tumour (S00036624) (A) and a calcaneal tumour (S00036606) (B) originally diagnosed as ABCs. A sacral tumour in
an 18-year-old female originally diagnosed with an ABC. The tumour shows blood-filled vascular spaces contained by septa (A1), and
scattered solid areas (A2), both of which contain numerous osteoclasts: a USP6 gene rearrangement is not detected. The tumour har-
boured a H3F3A p.G34W mutation after which the lesion was then reclassified as a giant cell tumour (GCT) with ABC change. A cal-
caneal tumour in a 22-year-old male originally diagnosed with an ABC. The X-ray reveals a well-defined lucency (B1), and the MRI
shows fluid–fluid levels (B2). The histology shows an osteoclast-rich predominantly cystic lesion (B3, B4). A H3F3B p.K36M mutation
was detected. The histology was reviewed and small areas with features of CB (B4) were detected. The tumour was reclassified as CB
with extensive ABC change.
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Targeted genetic analysis
Giant cell tumour of bone. A histological diagnosis of
GCT was favoured in 91 osteoclast-rich tumours: 83
were found to harbour a H3F3A p.G34W alteration
and alterations represented by p.G34R and p.G34M
were detected in two tumours (Table 2). No muta-
tions were detected in the H3F3B gene. The two
GCTs (femur S00033722, ulna S00033686) which
metastasised to the lung harboured a H3F3A
p.G34W mutation. Morphologically, both primary
tumours and the metastases showed the typical fea-
tures of a conventional GCT. Both patients are alive
and well and the tumours were classified as ‘benign
metastasising’ GCT [15].
Fluorescence in situ hybridisation (FISH) revealed
USP6 break-apart signals in 2/6 remaining wild type
(WT) GCT, both of which were located in the spine
(Table 2). In these 2 cases, the histology was re-
evaluated and considered compatible with ABC and the
diagnosis revised accordingly. Ten GCT with a H3F3A
p.G34W were also tested for USP6 rearrangements and
all were negative. Consequently, 85/89 (96%) GCT
showed mutations in H3F3A genes (Table 2).
Sixty GCT were screened for hotspot mutations in
12 genes in addition to H3F3A and H3F3B using the
Ion Torrent PGM. No mutations, specifically no
TP53, IDH1 and IDH2 alterations, were identified
(Supporting Information Table 2).
None of the 89 GCT presented in patients with
immature skeleton, although 2 female patients pre-
sented at the age of 15 and one at 17.
Chondroblastoma. All seven CB analysed by targeted
sequencing harboured a p.K36M mutation, five of
which were in the H3F3A and two in the H3F3B gene
(Table 2). Seven CB were analysed for USP6 rear-
rangements, including 4/77 cases that were WT for
H3F3A and H3F3B in our previous study (Table 1),
and the 3/7 cases from this study in which a p.K36M
alteration was identified (Table 2). None were
detected. No mutations in the hotspots in the Ion Tor-
rent PGM 14 gene panel assay were detected in 19 CB
harbouring p.K36M: these included 18 cases from the
previous study (Supporting Information Table 1, 2).
Aneurysmal bone cyst. Of 44 tumours where the fav-
oured initial histological diagnosis was ABC, 32
revealed a USP6 rearrangement by FISH: 27 showing
break-apart signals, with 5 showing deletions of the
telomeric end (Figure 1, Table 2). One of the remain-
ing cases (1/12) harboured a H3F3B p.K36M muta-
tion which on histological review revealed a tiny
fragment with features of a CB (Figure 1B). The
diagnosis was, therefore, revised. Two additional
cases (2/12) revealed H3F3A p.G34W mutation and
were considered to be compatible with GCT on histo-
logic re-evaluation (Figure 1A). The remaining 9/12
cases were WT for both the USP6 and H3.3 altera-
tions. The USP6 alterations were mutually exclusive
with H3.3 mutations. Reclassification of ABC on the
basis of the genetic finding in 3/44 lesions resulted in
a diagnosis of 41 ABC, 32 (78%) of which demon-
strated USP6 rearrangements (Table 2).
Osteoclast-rich tumours of the small bones of hand and
feet and patella. Twenty-eight osteoclast-rich tumours
of small bones of the hand (n 5 13), feet (n 5 14)
and patella (n 5 1) were studied, including three
cases from our previous study (Supporting Informa-
tion Table 1, 2). Sixteen tumours harboured a H3F3A
mutation, 14 of which involved a p.G34W alteration.
The other two alterations were represented by
p.G34L mutations (Supporting Information Table 1,
2). One tumour in the talus harboured a H3F3B
p.K36M substitution. On histological review a small
focus with features of a CB was seen and the tumour
was reclassified accordingly. USP6 break-apart sig-
nals were detected in 3/11 remaining cases that were
WT for H3F3A and H3F3B, and these were classified
as ABC, leaving 8/28 (29%) cases (patella, bone of
hand 32, bone of foot 35) without an alteration
with which to classify the disease. The USP6 rear-
rangement was mutually exclusive with H3.3 muta-
tions in these cases. Screening of the mutation
hotspots on Ion Torrent PGM failed to reveal any
additional mutations in the 24/28 cases.
Nonossifying fibroma, tenosynovial giant cell tumour,
osteoblastoma, osteoid osteoma, and giant cell granu-
loma of the jaw. Details of these tumours are included
in Supporting Information Table 2 and genetic altera-
tions in Table 2: 4/66 previously diagnosed NOF har-
boured H3F3A p.G34W alterations. These were
reclassified as GCT following review of histology
and imaging. No H3F3A and H3F3B mutations or
hotspot mutations were identified in the Ion Torrent
screen. Fifteen GCG of the jaws analysed by FISH
for USP6 rearrangements did not reveal a break-apart
signal or deletion of one the probes.
We screened 51 tenosynovial giant cell tumours,
21 osteoblastomas, 9 osteoid osteomas, and 78 GCG
of the jaw, three cases of genetically proven cherub-
ism and two cases of genetically proven Noonan syn-
drome. No p.G34 alterations in H3F3A or p.K36
alterations in the H3F3B were identified (Table 2).
H3F3A and H3F3B mutations in malignant osteoclast-
rich tumours. Ten cases classified as malignant
osteoclast-rich tumours were retrieved from the
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RNOH archives, eight of which were wild type (WT)
for H3F3A and H3F3B mutations (Table 3). On his-
tological review, four cases revealed features typical
of osteosarcoma in addition to osteoclast-rich areas.
These cases were reclassified as osteosarcoma with
osteoclast-rich areas. Of the four other WT cases,
three were composed predominantly of areas of
malignant GCT (Figure 2B). The remaining tumour
was a predominantly osteoclast-rich tumour which
had been reported as being ‘suspicious for malig-
nancy’ and revealed an IDH2 p.R172S mutation. On
review of the biopsy, a small fragment of mature
neoplastic cartilaginous tissue in addition to the
osteoclast-rich neoplasm was noted. The tumour was
mitotically active (20 mitoses/high power fields). No
cartilage was detected in the resection specimen
Figure 2. Photomicrographs and X-rays of a conventional (S00033682) (A), and malignant giant cell tumour (GCT) (S00030176) (B). A
central lytic tumour of the distal radius (A1). The histology is typical for GCT in which the stromal cells show no significant cytologi-
cal atypia (A2). An aggressive lytic lesion of the talus, which has broken through the cortex (B1). Microscopy shows features of a
malignant osteoclast-rich tumour in which the stromal cell are enlarged with nuclear pleomorphism and numerous mitoses, including
atypical forms (B3 and B4). Geographic-type tumour necrosis was also present (not shown).
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although an area showing a monotonous spindle cell
overgrowth was present (Supporting Information Fig-
ure 2). This histological observation associated with
the IDH2 p.R172S mutation supported a diagnosis of
a dedifferentiated chondrosarcoma in which the
dedifferentiated component was an osteoclast-rich
neoplasm. The tumour was reclassified accordingly.
Of the three patients whose tumours showed pre-
dominantly a malignant GCT component, one was
sited in the talus and the patient is well having expe-
rienced no recurrence following amputation with 24
months of follow-up (Figure 2B). The second was a
multicentric malignant GCT diagnosed in 2002. This
patient developed brain and lung metastasis and died
9 years after diagnosis. The third tumour developed
in the distal tibia and within 6 months of diagnosis
and amputation, the patient developed recurrent dis-
ease at the amputation stump and metastatic disease
in the pelvis.
One osteoclast-rich malignant tumour which har-
boured a H3F3A p.G34W mutation originated in the
distal tibia and within a short interval presented with
multifocal disease in the vertebrae, which revealed
unequivocal malignant features. The patient was
treated with resection and radiotherapy and is alive
with disease 20 years after diagnosis. Neither tissue
nor imaging from the original tumour was available
for review.
The second osteoclast-rich malignant tumour which
harboured a H3F3A p.G34W mutation was classified
as an unusual, high grade osteoclast-rich tumour with
adamantinoma-like features located in the right proxi-
mal tibia. Histological features typical of a conven-
tional adamantinoma were present and this
component merged with a high grade spindle cell sar-
comatous area partly infiltrated with large numbers
of osteoclasts. Sited in the subarticular space it was
considered more in keeping with a GCT because ada-
mantinomas generally occur in the diaphysis (Sup-
porting Information Figure 2). No TP53 mutations
were detected. The tumour was resected en bloc: the
patient developed multiple spinal metastases and died
of disease 7 months later. The different histological
areas were microdissected and all revealed the
H3F3A p.G34W alteration (Table 3). H3.3 mutations
were not detected in six other cases of osteofibrous
dysplasia and eight cases of adamantinoma (Table 2).
Overall our observations suggest that the presence
of H3F3A p.G34W mutations does not entirely
exclude malignancy in osteoclast-rich tumours. How-
ever, H3F3A p.G34W mutations appear to be an
almost essential feature of GCT that will aid patho-
logical evaluation of bone tumours, especially when
confronted with small needle core biopsies (see
algorithm-based for diagnosis decision Supporting
Information Figure 3).
Discussion
Whole genome/exome sequencing of 6 GCT showed
remarkably few somatic changes, other than the
occurrence of H3F3A mutations. In this way, GCT
genomes showed similarities with previously reported
CB genomes [2] which reflects overlapping features
of the two tumour types, including the osteoclast-rich
morphology, their site of occurrence and their biolog-
ical behaviour. The notable difference between these
tumours is the association of cartilaginous differentia-
tion in CB with the H3.3 K36M alteration, the major-
ity of which occur in H3F3B, whereas 96% of the
mutations in GCT occur in H3F3A involving p.G34.
The finding of highly recurrent H3.3 substitutions in
the absence of other recurrent alterations in both pri-
mary and recurrent disease also implies that these
mutations in both GCT and CB represent essential
oncogenic drivers. It is noteworthy that in the two
cases of ‘benign’ metastatic disease no driver muta-
tion other than p.G34W alterations were found in the
primary and distant lesions.
In our previous publication [2], we remarked on
the exquisite specificity of individual H3.3 mutations
for different bone and brain tumour types. Here, we
confirm that the vast majority (83/89) of GCT altera-
tions occur in H3F3A and involve p.G34W. How-
ever, we also detected an overlap of specific H3.3
mutations and tumour types in a minority of cases.
We found that p.G34 substitutions in GCT involve
on rare occasions H3F3A p.G34R which is com-
monly seen in paediatric glioblastoma. In addition,
p.G34M was also detected in a single GCT, a substi-
tution previously reported only once in diffuse intrin-
sic pontine glioma [16]. In contrast to the occurrence
of p.G34R and p.G34M in aggressive brain tumours,
in which TP53 mutations are also seen [17], the 3
GCT with these alterations followed a typical clinical
course and did not harbour TP53 mutations, with 2/3
having at least 5 years follow-up (p.G34R—2009;
p.G34M—2004). Finally, we also confirm that
p.G34L mutations are rare and 2/3 occurred in small
bones of the hands and feet. This mutation, like
p.G34W, appears to be confined to bone tumours,
having not been reported in primary brain tumours.
In contrast to the high prevalence of H3.3 muta-
tions in GCT and CB, these are rare in malignant pri-
mary bone tumours. Specifically, H3.3 mutations
have previously been reported to occur in 3/113
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osteosarcoma, 1/15 clear cell chondrosarcoma and 1/
75 central chondrosarcoma [2,3]. A novel finding in
this study is the presence of a H3F3A p.G34W altera-
tion in an unusual high grade osteoclast-rich tumour
with adamantinoma-like features thereby providing
further evidence to link an osteoclast-rich phenotype
with a H3.3 mutation. However, the mutation was
present in both osteoclast-rich and osteoclast-
deficient areas. Further research is required to explain
the genotype–phenotype association between H3F3A
p.G34W and osteoclast recruitment. This is only the
second time that the p.G34W alteration has been
associated with a malignant bone tumour. The first
was reported in an osteosarcoma but no histological
or clinical details of this case were reported [3]. We
have previously reported 2 osteosarcomas harbouring
a H3.3 mutation, namely p.G34R in H3F3A and in
H3F3B. Taken together these findings indicate that
malignancy in bone tumours cannot be excluded on
detection of H3.3 mutations. In contrast, diagnosis of
a GCT in the absence of a H3F3A alteration should
be made with considerable caution in view of the
high prevalence of H3F3A mutations in GCT, 95%
(132/139 from current and previous study).
The role of H3.3 genes in human neoplasms has
been brought to the fore by large scale sequencing
studies undertaken on paediatric brain tumours [18].
One of the most intriguing aspects of these mutations
is the specificity of mutations for age and anatomical
location of these tumours. Similarly, our work pre-
sented here confirms our previous observation of
tumour type specificity of H3.3 mutations in further
bone tumour subtypes. Mutations at p.G34 were con-
fined to tumours harbouring cells of the osteoclastic
lineage, whereas mutations in p.K36 occurred solely
in bone tumour of chondroblastic lineage. Further-
more, we found that mutations of H3F3B at G34 are
exceedingly rare and have to date only been
described in a single case of osteosarcoma. Finally,
the association of the rare p.G34L mutation with
tumours of small bones, caused by a double substitu-
tion, is noteworthy. The point mutations of H3F3A in
brain tumours localise close to sites of post-
translational modification of p.K27 and p.K36 result-
ing in methylation of H3K27 (transcriptional repres-
sion) and H3K36 (transcriptional elongation and
splicing). It is, therefore, likely that these mutations,
accompanied by subsequent post-translational modifi-
cations, exert their oncogenic effects through altered
gene expression profiles in specific cells and in a
particular developmental context. This proposition is
supported by in vitro experimental evidence using
glioma cell lines showing a clear link between his-
tone mutation, methylation, gene expression and
tumourigenesis [18,19]. The specific roles that H3.3
p.G34 mutations may have in tumourigenesis are still
not known.
Kato Kaneko et al recently reported a high preva-
lence of IDH2 alterations in GCT (16/20 cases): 13
were detected by direct Sanger sequencing and 3 by
subcloning the PCR product and subsequent sequenc-
ing [9]. By contrast, we did not find any IDH1 or IDH2
mutations in the majority of 84 GCT and 22 osteoclast-
rich tumours of the small bones of the hands and feet.
A canonical IDH2 mutation was detected in one of our
cases but, on histological re-evaluation, we considered
this case to represent a dedifferentiated chondrosar-
coma. Although a rare finding, this could soon have
therapeutic implications in view of the development of
IDH1/2 inhibitors, and a vaccine that targets mutant
IDH1 [20,21], and therefore, this case highlights the
utility of genotyping tumours for diagnostic purposes.
The reason for the findings by Kato Kaneko et al is
unclear: we consider it is unlikely to be explained by a
different cohort of tumours in view of the numbers of
cases that we have analyzed. It is unlikely to be a sensi-
tivity issue as the Ion Torrent platform is very sensi-
tive. DNA contamination is a possibility, particularly if
subcloning of the IDH1/2 genes has been performed
previously in this laboratory.
The presence of H3F3A p.G34 alterations in 96%
of GCT along with their absence in other benign
bone tumours including CB, osteoid osteoma, osteo-
blastoma, tenosynovial giant cell tumour and chon-
dromyxoid fibroma provides evidence that H3F3A
p.G34 mutations are a highly sensitive and specific
marker for GCT. It is particularly valuable for distin-
guishing between those tumours with mutually exclu-
sive alterations such as GCT and CB, and GCT and
ABC, which harbour USP6 fusion genes in 75% of
cases [5,22]. In contrast, there is no genetic alteration
characteristic of NOF. Although H3F3A p.G34W
alterations were detected in 4/66 cases, we propose
that these cases represent misdiagnoses, based on a
multidisciplinary review of these cases. Indeed, in all
cases studied here in which genotype was discordant
with the original pathological diagnosis, we reviewed
histology and imaging. In all but one case, we altered
our original diagnosis in favour of the genetic find-
ings. Nevertheless, using the detection of H3.3 altera-
tions in clinical practice would be more robust, if
mutually exclusive markers were available for each
of these tumour types, or if a second recurrent altera-
tion was present in these tumours.
GCG of the small bone of the hands and feet and
GCG of the jaws are considered to be distinct from
conventional GCT (WHO classification [1]). It has
been argued that these lesions represent a ‘solid
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variant’ of a primary ABC [23]. Agaram et al recently
provided molecular evidence for this proposition by
demonstrating USP6 rearrangements in 8/9 GCG of
the hands and feet [4]. They also reported no USP6
alterations in eight conventional GCT, two of which
were located in the finger. The combined data from
our current and previous study [2] provide further evi-
dence for the occurrence of solid variants of ABC in
the bones of the hands and feet, and show for the first
time that GCT also represents a significant number of
osteoclast-rich tumours at these sites, highlighting the
benefit of using these mutually exclusive genetic alter-
ations for distinguishing these entities.
It is noteworthy that neither H3.3 nor USP6 altera-
tions were detected in any of the 78 GCG of the jaw
in our study indicating that GCG of the jaws are dis-
tinct from both GCT and solid variants of primary
ABC. From a clinical perspective, it is important to
note that osteoclast-rich lesions of the jaw also occur
in patients with Noonan syndrome, neurofibromatosis
(NF1) and cherubism (SH2BP2), and that these
should be excluded before provision of a diagnosis of
GCG [24,25]. Not all GCG included, in this study
had been analysed for these alterations and it is,
therefore, possible that some of the cases diagnosed
as GCG represent syndrome-related lesions.
The introduction of screening of bone tumours for
H3.3 alterations along with other common bone cancer
genes including IDH1/2 alterations in cartilaginous
tumours [8,9], GRM1 rearrangements of chondromyxoid
fibromas [26] and USP6 alterations in ABC [5,6,22]
adds to the armoury with which pathologists can provide
accurate diagnoses. Although H3.3 alterations does not
stratify patients to therapeutic agents at this time, in the
future this may be the case [20,21]. The study also high-
lights the changes required in laboratory practices if
these new findings and those yet to be discovered are to
be introduced effectively into clinical medicine.
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SUPPLEMENTARY MATERIAL ON THE INTERNET
SUPPLEMENTARY MATERIAL ON THE INTERNET
The following supplementary material may be found in the online version of this article:
Supplementary methods:
Table S1. Samples of giant cell tumour (GCT) and chondroblastoma (CB) with H3.3 alterations published in the previous study [2] with addi-
tional results to the original table published for USP6 analysis and targeted sequencing.
Table S2. Samples with diagnoses, clinical and genetic data from this study.
Table S3. Sample type and distribution.
Table S4. Primer sequences and description of the hot-spot targeted with PGM sequencer.
Table S5. Somatic substitutions and indels.
Figure S1. Genome-wide copy number profile of five giant cell tumours of bone. 4/5 tumours show essentially no copy number changes. Bot-
tom: PD7524a harbours telomeric LOH in chromosomes 5q and 8p (arrows) assessed by Affymetrix SNP6. The smaller changes seen are likely
to represent ‘noise’ as the sample was shown to be of low cellularity (33%). X-axis: genomic position (ascending). Y-axis: copy number. Num-
bers in plot refer to chromosome. Red and green: major and minor allele, respectively.
Figure S2. (A) Photomicrographs of a tumour presenting in a 59 year old originally diagnosed as a GCT. The biopsy showed a fragment of
mature hyaline cartilage and an osteoclast-rich mitotically active tumour. The tumour was wild type for H3F3 and an IDH2 alteration was
detected. Following re-evaluation and in the context of the genetics a diagnosis of a dedifferentiated chondrosarcoma was made. (B) Radio-
graph and photomicrographs of subarticular lytic tumour in the proximal tibia. The imaging suggested a GCT but the histology showed a
mitotically active spindle cell tumour with epithelioid differentiation, supported by the cytokeratin expression (inset) and an osteoclast-rich
area. The tumour was classified as an unusual high grade osteoclast-rich tumour with adamantinoma-like features.
Figure S3. Algorithm-based schema illustrating the approach to reaching a diagnosis of osteoclast-rich tumours.
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